Review





Similar Products

gene exp cd274 mm03048248 m1  (Thermo Fisher)
96
Thermo Fisher gene exp cd274 mm03048248 m1
(A) Representative immunofluorescence images <t>showing</t> <t>PD-L1</t> expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of CD8 + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.
Gene Exp Cd274 Mm03048248 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp cd274 mm03048248 m1/product/Thermo Fisher
Average 96 stars, based on 1 article reviews
gene exp cd274 mm03048248 m1 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
rabbit anti pd l1 antibody  (Bioss)
94
Bioss rabbit anti pd l1 antibody
In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Rabbit Anti Pd L1 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti pd l1 antibody/product/Bioss
Average 94 stars, based on 1 article reviews
rabbit anti pd l1 antibody - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
pd l1 monoclonal antibody  (Proteintech)
96
Proteintech pd l1 monoclonal antibody
In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Pd L1 Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pd l1 monoclonal antibody/product/Proteintech
Average 96 stars, based on 1 article reviews
pd l1 monoclonal antibody - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
pdl1  (Sino Biological)
95
Sino Biological pdl1
In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Pdl1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pdl1/product/Sino Biological
Average 95 stars, based on 1 article reviews
pdl1 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
murine pd l1  (Sino Biological)
94
Sino Biological murine pd l1
In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Murine Pd L1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/murine pd l1/product/Sino Biological
Average 94 stars, based on 1 article reviews
murine pd l1 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
human pd l1  (Sino Biological)
94
Sino Biological human pd l1
In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Human Pd L1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human pd l1/product/Sino Biological
Average 94 stars, based on 1 article reviews
human pd l1 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
resource source identifier murine pd l1 fc fusion protein sinobiological 50010 m02h lipopolysaccharide lps  (Sino Biological)
94
Sino Biological resource source identifier murine pd l1 fc fusion protein sinobiological 50010 m02h lipopolysaccharide lps
In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Resource Source Identifier Murine Pd L1 Fc Fusion Protein Sinobiological 50010 M02h Lipopolysaccharide Lps, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/resource source identifier murine pd l1 fc fusion protein sinobiological 50010 m02h lipopolysaccharide lps/product/Sino Biological
Average 94 stars, based on 1 article reviews
resource source identifier murine pd l1 fc fusion protein sinobiological 50010 m02h lipopolysaccharide lps - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
rat pd l1 his  (Sino Biological)
93
Sino Biological rat pd l1 his
In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Rat Pd L1 His, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat pd l1 his/product/Sino Biological
Average 93 stars, based on 1 article reviews
rat pd l1 his - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
human pd l1 his  (Sino Biological)
95
Sino Biological human pd l1 his
In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Human Pd L1 His, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human pd l1 his/product/Sino Biological
Average 95 stars, based on 1 article reviews
human pd l1 his - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
sino biological cat 90251 c08h  (Sino Biological)
94
Sino Biological sino biological cat 90251 c08h
In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of <t>PD-L1</t> (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Sino Biological Cat 90251 C08h, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sino biological cat 90251 c08h/product/Sino Biological
Average 94 stars, based on 1 article reviews
sino biological cat 90251 c08h - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


(A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of CD8 + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.

Journal: bioRxiv

Article Title: “Tumor-to-endothelium mitochondrial transfer licenses endothelial cells for CD8 + T cell recognition via mitochondrial neoantigen presentation”

doi: 10.64898/2026.01.30.702567

Figure Lengend Snippet: (A) Representative immunofluorescence images showing PD-L1 expression in naïve kidney and RENCA tumors (Hoechst, nuclei; PD-L1, red). IF and qPCR quantification of PD-L1 signal is shown on the right. (B) From top to bottom, schematic of RENCA tumor implantation and treatment schedule, longitudinal tumor growth monitoring and endpoint analyses. (C) IFN γ ELISPOT responses of CD8 + T cells to BMDCs pulsed with TAMAs peptides and/or RENCA mitochondrial lysate. Peptide- and lysate-driven responses are shown as the summed response (spot-forming cells, SFC, per indicated number of CD8 + T cells). (D) Flow cytometric quantification of intratumoral CD8 + T cells across treatment groups. Right, correlation between tumor volume and CD8 + T cell abundance. (E) Immunoblot showing perforin expression in tumors across treatment groups (VCL loading control) with densitometric quantification. (F) Flow cytometric analysis of activated CD8 + T cells (CD107a + ) across treatment groups and correlation with tumor volume. Data are shown as mean ± s.e.m. unless otherwise indicated. Statistical comparisons were performed using one-way ANOVA with multiple-comparison correction.

Article Snippet: Housekeeping gene Rn18s (Mm03928990_g1), PDL-1 (Mm03048248_m1), Perforin (Mm00812512_m1), Ang1 (Mm01233546_g1), Ang2 (Mm00657574_s1), VECAD/Cdh5 (Mm00486938_m1), Vcam1 (Mm01320970_m1), Cxcl10 (Mm00445235_m1), Cxcl11 (Mm00444662_m1), Cxcl9 (Mm00434946_m1), Vegfa (Mm00437306_m1), Pdgfb (Mm00440677_m1), Irf3 (Mm00516784_m1), CD8a (Mm01182107_g1), Ifnγ (Mm01168134_m1), Il12a (Mm00434169_m1), Il12b (Mm01288989_m1), and Gzmb (Mm00442837_m1), TNF (Mm00443258_m1), PTEN (Mm00477208_m1), Itgax (Mm00498701_m1), Tnfsf10 (Mm01283606_m1), Tnfrsf1a (Mm00441883_g1).

Techniques: Immunofluorescence, Expressing, Tumor Implantation, Enzyme-linked Immunospot, Western Blot, Control, Comparison

In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of PD-L1 (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Journal: Materials Today Bio

Article Title: Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling

doi: 10.1016/j.mtbio.2025.102749

Figure Lengend Snippet: In vitro reprogramming of the tumor microenvironment (TME) by Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence analysis and quantitative analysis of HMGB1 exposure (A, red) and CRT exposure (B, red) in B16-F10 cells following different treatments. Blue: DAPI (n = 3). ( C ) Immunofluorescence staining of CD86,iNOS and CD206 in macrophages (n = 3). ( D ) Immunofluorescence staining of PD-L1 (n = 3). ( E-G )Quantitative analysis of CD86,iNOS and CD206 expression. ( H ) Quantitative analysis of PD-L1 expression (n = 3). Data are presented as Mean ± SD. Pairwise comparisons against the control group were performed using Student's t-test; differences among multiple groups were assessed by one-way ANOVA. Ns: not significant (P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus Ctrl. # P < 0.05, ## P < 0.01, ### P < 0.001 versus the IL-4 group. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Alexa Fluor® 594 AffiniPure Goat Anti-Rabbit IgG (H + L) (Cat. No. 111-585-003, dilution: 1:250) was sourced from Jackson ImmunoResearch Inc. Rabbit anti-CD86 antibody (Cat. No. WL05184, dilution: 1:200), rabbit anti-iNOS antibody (Cat. No. WL0992a, dilution: 1:200), rabbit anti-CD206 antibody (Cat. No. WL06177, dilution: 1:200), and fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG (H + L) (Cat. No. WLA032, dilution: 1:200) were purchased from Wanlei Bio-Tech Co., Ltd. Rabbit anti-PD-L1 antibody (Cat. No. bs-1103R, dilution: 1:250) was obtained from Beijing Bioss Biotechnology Co., Ltd. PerCP/Cyanine5.5 anti-mouse CD45 Recombinant Antibody (Cat. No. 157612, dilution: 1:200), PE anti-mouse CD11c Antibody (Cat. No. 117308, dilution: 1:200), APC anti-mouse CD86 Antibody (Cat. No. 159216, dilution: 1:200), FITC anti-mouse CD80 Antibody (Cat. No. 104706, dilution: 1:200), PE/Cyanine7 anti-mouse I-A b Antibody (Cat. No. 116420, dilution: 1:200), Zombie R718TM Fixable Viability Kit (Cat. No. 423116, dilution: 1:200), FITC anti-mouse CD3 Antibody (Cat. No. 100204, dilution: 1:100), PE anti-mouse CD4 Antibody (Cat. No. 100408, dilution: 1:200), APC/Cyanine7 anti-mouse CD8a Antibody (Cat. No. 100714, dilution: 1:200), APC anti-mouse/human CD11b Antibody (Cat. No. 101212, dilution: 1:200), APC/FireTM 750 anti-mouse F4/80 Antibody (Cat. No. 123152, dilution: 1:200), PE/DazzleTM 594 anti-mouse CD206 (MMR) Antibody (Cat. No. 141732, dilution: 1:200), and PE/Cyanine7 anti-mouse CD86 Antibody (Cat. No. 159208, dilution: 1:200) were purchased from BioLegend.

Techniques: In Vitro, Immunofluorescence, Staining, Expressing, Control

In vivo immune activation of Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence staining of HMGB1 (A, red) and CRT (B, red) in tumor tissues following various treatments. Blue: DAPI; scale bars: 100 μm. (n = 5). ( C, D ) Immunofluorescent staining of CD206 (C, green) and CD86 (D, green) in tumor sections. Blue: DAPI; scale bars: 100 μm. (n = 5). ( E ) Immunofluorescence staining of PD-L1 expression (red) in tumors across treatment groups. Blue: DAPI; scale bars: 100 μm. (n = 5). ( F, G ) Flow cytometry analysis of MHC-II expression (F) and CD80 + +CD86 + populations (G) in DCs from spleens. (n = 5). ( H ) Immunofluorescence co-staining of CD4 (green) and CD8 (red) in tumor tissues. Blue: DAPI; scale bars: 100 μm. (n = 5). Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Journal: Materials Today Bio

Article Title: Metformin glycyrrhetinic acid binary injectable hydrogel for synergistic tumor immunotherapy via spatiotemporal microenvironment remodeling

doi: 10.1016/j.mtbio.2025.102749

Figure Lengend Snippet: In vivo immune activation of Fe 3 O 4 NPs@Met-GA-H. ( A, B ) Immunofluorescence staining of HMGB1 (A, red) and CRT (B, red) in tumor tissues following various treatments. Blue: DAPI; scale bars: 100 μm. (n = 5). ( C, D ) Immunofluorescent staining of CD206 (C, green) and CD86 (D, green) in tumor sections. Blue: DAPI; scale bars: 100 μm. (n = 5). ( E ) Immunofluorescence staining of PD-L1 expression (red) in tumors across treatment groups. Blue: DAPI; scale bars: 100 μm. (n = 5). ( F, G ) Flow cytometry analysis of MHC-II expression (F) and CD80 + +CD86 + populations (G) in DCs from spleens. (n = 5). ( H ) Immunofluorescence co-staining of CD4 (green) and CD8 (red) in tumor tissues. Blue: DAPI; scale bars: 100 μm. (n = 5). Data are presented as mean ± SD. Statistical significance was determined by one-way ANOVA. Ns: not significant ( P > 0.05); ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus the Ctrl. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: Alexa Fluor® 594 AffiniPure Goat Anti-Rabbit IgG (H + L) (Cat. No. 111-585-003, dilution: 1:250) was sourced from Jackson ImmunoResearch Inc. Rabbit anti-CD86 antibody (Cat. No. WL05184, dilution: 1:200), rabbit anti-iNOS antibody (Cat. No. WL0992a, dilution: 1:200), rabbit anti-CD206 antibody (Cat. No. WL06177, dilution: 1:200), and fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG (H + L) (Cat. No. WLA032, dilution: 1:200) were purchased from Wanlei Bio-Tech Co., Ltd. Rabbit anti-PD-L1 antibody (Cat. No. bs-1103R, dilution: 1:250) was obtained from Beijing Bioss Biotechnology Co., Ltd. PerCP/Cyanine5.5 anti-mouse CD45 Recombinant Antibody (Cat. No. 157612, dilution: 1:200), PE anti-mouse CD11c Antibody (Cat. No. 117308, dilution: 1:200), APC anti-mouse CD86 Antibody (Cat. No. 159216, dilution: 1:200), FITC anti-mouse CD80 Antibody (Cat. No. 104706, dilution: 1:200), PE/Cyanine7 anti-mouse I-A b Antibody (Cat. No. 116420, dilution: 1:200), Zombie R718TM Fixable Viability Kit (Cat. No. 423116, dilution: 1:200), FITC anti-mouse CD3 Antibody (Cat. No. 100204, dilution: 1:100), PE anti-mouse CD4 Antibody (Cat. No. 100408, dilution: 1:200), APC/Cyanine7 anti-mouse CD8a Antibody (Cat. No. 100714, dilution: 1:200), APC anti-mouse/human CD11b Antibody (Cat. No. 101212, dilution: 1:200), APC/FireTM 750 anti-mouse F4/80 Antibody (Cat. No. 123152, dilution: 1:200), PE/DazzleTM 594 anti-mouse CD206 (MMR) Antibody (Cat. No. 141732, dilution: 1:200), and PE/Cyanine7 anti-mouse CD86 Antibody (Cat. No. 159208, dilution: 1:200) were purchased from BioLegend.

Techniques: In Vivo, Activation Assay, Immunofluorescence, Staining, Expressing, Flow Cytometry